Pergolide: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(7 intermediate revisions by the same user not shown)
Line 7: Line 7:
|indication=[[Parkinson's disease]] as an adjunctive treatment with [[carbidopa]]/[[levodopa]]
|indication=[[Parkinson's disease]] as an adjunctive treatment with [[carbidopa]]/[[levodopa]]
|hasBlackBoxWarning=Yes
|hasBlackBoxWarning=Yes
|blackBoxWarningTitle=<b><span style="color:#FF0000;">Cardiac Valvulopathy and Fibrotic Complications</span></b>
|adverseReactions=[[dyskinesia]], [[hallucinations]], [[somnolence]], [[insomnia]], [[nausea]], [[constipation]], [[diarrhea]], [[dyspepsia]] and [[rhinitis]]
|blackBoxWarningBody=<i><span style="color:#FF0000;">Cardiac Valvulopathy:</span></i> The use of pergolide has been shown to increase the risk of cardiac valvular disease involving one or more valves.  Some patients have required valve replacement, and deaths have been reported. Cases have been reported after exposures to pergolide ranging from several months to several years.  The histopathology of explanted valves is similar to that of other drug-induced valvulopathies. Precise risk estimates of pergolide-induced cardiac valvular disease are not available.
|blackBoxWarningTitle=<span style="color:#FF0000;">Cardiac Valvulopathy and Fibrotic Complications</span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">Cardiac Valvulopathy:</span></i>  
*The use of pergolide has been shown to increase the risk of cardiac valvular disease involving one or more valves.  Some patients have required valve replacement, and deaths have been reported. Cases have been reported after exposures to pergolide ranging from several months to several years.  The histopathology of explanted valves is similar to that of other drug-induced valvulopathies. Precise risk estimates of pergolide-induced cardiac valvular disease are not available.
*Specific risk factors predisposing patients to developing cardiac valvular disease with pergolide have not been identified.  Cardiac valvulopathy has been reported with all doses of pergolide; however, available data suggest that the risk may be greater with higher doses.  Doses of pergolide above 5 mg/day are not recommended.
*Pergolide is not recommended for use in patients with a history of cardiac valvulopathy.
*Before initiating treatment with pergolide, all patients should undergo a cardiovascular evaluation, including an echocardiogram, to determine whether valvular disease is present and to provide a baseline for subsequent monitoring.
*Although the risk of disease progression in patients with asymptomatic valvular disease is unknown, pergolide ordinarily should not be initiated if valvulopathy is detected at screening.
*All patients taking pergolide should undergo periodic echocardiograms to screen for the development of valvulopathy. Patients should also be monitored for signs and symptoms of valvulopathy, including dyspnea, edema, congestive heart failure and new cardiac murmurs. If a patient develops these signs or symptoms, consideration should be given to suspending treatment with pergolide until a full diagnostic evaluation, including echocardiogram, has been performed. Pergolide should ordinarily be discontinued if a patient is diagnosed with cardiac valvular disease. In some cases, signs and/or symptoms of cardiac valvulopathy improved after discontinuation of pergolide.


Specific risk factors predisposing patients to developing cardiac valvular disease with pergolide have not been identified.  Cardiac valvulopathy has been reported with all doses of pergolide; however, available data suggest that the risk may be greater with higher doses.  Doses of pergolide above 5 mg/day are not recommended (seeDOSAGE & ADMINISTRATION).


Pergolide is not recommended for use in patients with a history of cardiac valvulopathy.
<i><span style="color:#FF0000;">Fibrotic Complications:</span></i>  
 
*Case reports have demonstrated that pergolide increases the risk of fibrotic complications including pulmonary, pleural, and/or retroperitoneal fibrosis, pericarditis, pleuritis, and pericardial and/or pleural effusions.  Cases have been reported after exposures to pergolide ranging from about one to several years.  Precise risk estimates of pergolide-induced fibrotic complications are not available.
Before initiating treatment with pergolide, all patients should undergo a cardiovascular evaluation, including an echocardiogram, to determine whether valvular disease is present and to provide a baseline for subsequent monitoring.  Although the risk of disease progression in patients with asymptomatic valvular disease is unknown, pergolide ordinarily should not be initiated if valvulopathy is detected at screening.
*Specific risk factors predisposing patients to developing fibrotic complications with pergolide have not been identified.  Fibrotic complications have been reported with all therapeutic doses of pergolide.
 
*Pergolide is not recommended for use in patients with a history of fibrotic conditions.
All patients taking pergolide should undergo periodic echocardiograms to screen for the development of valvulopathy. Patients should also be monitored for signs and symptoms of valvulopathy, including dyspnea, edema, congestive heart failure and new cardiac murmurs. If a patient develops these signs or symptoms, consideration should be given to suspending treatment with pergolide until a full diagnostic evaluation, including echocardiogram, has been performed. Pergolide should ordinarily be discontinued if a patient is diagnosed with cardiac valvular disease. In some cases, signs and/or symptoms of cardiac valvulopathy improved after discontinuation of pergolide.
*Patients should also be monitored for signs and symptoms of fibrotic complications, including dyspnea, persistent edema, cough, congestive heart failure, new cardiac rub, and/or signs of urinary tract obstruction. If a patient develops these signs or symptoms, consideration should be given to suspending treatment with pergolide until a full diagnostic evaluation has been performed. Pergolide should ordinarily be discontinued if a patient is diagnosed with a specific fibrotic complication. In some cases, signs and/or symptoms of fibrotic complications improved after discontinuation of pergolide.
 
|fdaLIADAdult=*Administration of Pergolide should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
 
*Pergolide is usually administered in divided doses 3 times per day. During dosage titration, the dosage of concurrent [[l-dopa]]/[[carbidopa]] may be cautiously decreased.
<i><span style="color:#FF0000;">Fibrotic Complications:</span></i> Case reports have demonstrated that pergolide increases the risk of fibrotic complications including pulmonary, pleural, and/or retroperitoneal fibrosis, pericarditis, pleuritis, and pericardial and/or pleural effusions.  Cases have been reported after exposures to pergolide ranging from about one to several years.  Precise risk estimates of pergolide-induced fibrotic complications are not available.
*In clinical studies, the mean therapeutic daily dosage of Pergolide was 3 mg/day. The average concurrent daily dosage of [[l-dopa]]/[[carbidopa]] (expressed as [[l-dopa]]) was approximately 650 mg/day. The efficacy of Pergolide at doses above 5 mg/day has not been systematically evaluated.  Doses of pergolide above 5 mg/day are not recommended.
 
Specific risk factors predisposing patients to developing fibrotic complications with pergolide have not been identified.  Fibrotic complications have been reported with all therapeutic doses of pergolide.
 
Pergolide is not recommended for use in patients with a history of fibrotic conditions.
 
Patients should also be monitored for signs and symptoms of fibrotic complications, including dyspnea, persistent edema, cough, congestive heart failure, new cardiac rub, and/or signs of urinary tract obstruction. If a patient develops these signs or symptoms, consideration should be given to suspending treatment with pergolide until a full diagnostic evaluation has been performed. Pergolide should ordinarily be discontinued if a patient is diagnosed with a specific fibrotic complication. In some cases, signs and/or symptoms of fibrotic complications improved after discontinuation of pergolide.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Pergolide in adult patients.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Pergolide in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Pergolide in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Pergolide in adult patients.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Pergolide in pediatric patients.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Pergolide in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Pergolide in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Pergolide in pediatric patients.
|contraindications=Pergolide is contraindicated in patients who are [[hypersensitive]] to this drug or other [[ergot]] derivatives.
|contraindications=*Pergolide is contraindicated in patients who are [[hypersensitive]] to this drug or other [[ergot]] derivatives.
|warnings='''[[Cardiac Valvulopathy]] and Fibrotic Complications'''
|warnings=====[[Cardiac Valvulopathy]] and Fibrotic Complications====
 
*'''Falling Asleep During Activities of Daily Living'''—Patients treated with Pergolide have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles which sometimes resulted in accidents. Although many of these patients reported [[somnolence]] while on Pergolide  some perceived that they had no warning signs such as excessive [[drowsiness]], and believed that they were alert immediately prior to the event. Some of these events had been reported as late as 1 year after the initiation of treatment.
'''Falling Asleep During Activities of Daily Living—Patients treated with Permax have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles which sometimes resulted in accidents. Although many of these patients reported [[somnolence]] while on Permax, some perceived that they had no warning signs such as excessive [[drowsiness]], and believed that they were alert immediately prior to the event. Some of these events had been reported as late as 1 year after the initiation of treatment.'''
*'''[[Somnolence]] is a common occurrence in patients receiving Pergolide''' — Many clinical experts believe that falling asleep while engaged in activities of daily living always occurs in a setting of preexisting somnolence, although patients may not give such a history. For this reason, prescribers should continually reassess patients for [[drowsiness]] or [[sleepiness]], especially since some of the events occur well after the start of treatment. Prescribers should also be aware that patients may not acknowledge [[drowsiness]] or sleepiness until directly questioned about drowsiness or sleepiness during specific activities.
 
*Before initiating treatment with Pergolide, patients should be advised of the potential to develop [[drowsiness]] and specifically asked about factors that may increase the risk with Pergolide such as concomitant [[sedating medications]] or the presence of [[sleep disorders]]. If a patient develops significant daytime sleepiness or episodes of falling asleep during activities that require participation (e.g., conversations, eating, etc.), Pergolide should ordinarily be discontinued. *If a decision is made to continue Pergolide, patients should be advised to not drive and to avoid other potentially dangerous activities.
'''[[Somnolence]] is a common occurrence in patients receiving Permax. Many clinical experts believe that falling asleep while engaged in activities of daily living always occurs in a setting of preexisting somnolence, although patients may not give such a history. For this reason, prescribers should continually reassess patients for [[drowsiness]] or [[sleepiness]], especially since some of the events occur well after the start of treatment. Prescribers should also be aware that patients may not acknowledge [[drowsiness]] or sleepiness until directly questioned about drowsiness or sleepiness during specific activities.'''
**While dose reduction may reduce the degree of [[somnolence]], there is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living.
 
*'''Symptomatic [[Hypotension]]''' — In clinical trials, approximately 10% of patients taking pergolide with [[l-dopa]] versus 7% taking placebo with [[l-dopa]] experienced symptomatic [[orthostatic hypotension]] and/or [[sustained hypotension]], especially during initial treatment. With gradual dosage titration, tolerance to the hypotension usually develops. It is therefore important to warn patients of the risk, to begin therapy with low doses, and to increase the dosage in carefully adjusted increments over a period of 3 to 4 weeks.
'''Before initiating treatment with Permax, patients should be advised of the potential to develop [[drowsiness]] and specifically asked about factors that may increase the risk with Permax such as concomitant [[sedating medications]] or the presence of [[sleep disorders]]. If a patient develops significant daytime sleepiness or episodes of falling asleep during activities that require participation (e.g., conversations, eating, etc.), Permax should ordinarily be discontinued. If a decision is made to continue Permax, patients should be advised to not drive and to avoid other potentially dangerous activities.'''
*'''[[Hallucinosis]]'''— In controlled trials, pergolide with [[l-dopa]] caused [[hallucinosis]] in about 14% of patients as opposed to 3% taking placebo with [[l-dopa]]. This was of sufficient severity to cause discontinuation of treatment in about 3% of those enrolled; tolerance to this untoward effect was not observed.
 
*'''Fatalities'''— In the placebo-controlled trial, 2 of 187 patients treated with placebo died as compared with 1 of 189 patients treated with pergolide. Of the 2299 patients treated with pergolide in premarketing studies evaluated as of October 1988, 143 died while on the drug or shortly after discontinuing it. Because the patient population under evaluation was elderly, ill, and at high risk for death, it seems unlikely that pergolide played any role in these deaths, but the possibility that pergolide shortens survival of patients cannot be excluded with absolute certainty.
'''While dose reduction may reduce the degree of [[somnolence]], there is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living.'''
 
Symptomatic [[Hypotension]] — In clinical trials, approximately 10% of patients taking pergolide with [[l-dopa]] versus 7% taking placebo with [[l-dopa]] experienced symptomatic [[orthostatic hypotension]] and/or [[sustained hypotension]], especially during initial treatment. With gradual dosage titration, tolerance to the hypotension usually develops. It is therefore important to warn patients of the risk, to begin therapy with low doses, and to increase the dosage in carefully adjusted increments over a period of 3 to 4 weeks.
 
*[[Hallucinosis]]— In controlled trials, pergolide with [[l-dopa]] caused [[hallucinosis]] in about 14% of patients as opposed to 3% taking placebo with [[l-dopa]]. This was of sufficient severity to cause discontinuation of treatment in about 3% of those enrolled; tolerance to this untoward effect was not observed.
 
*Fatalities— In the placebo-controlled trial, 2 of 187 patients treated with placebo died as compared with 1 of 189 patients treated with pergolide. Of the 2299 patients treated with pergolide in premarketing studies evaluated as of October 1988, 143 died while on the drug or shortly after discontinuing it. Because the patient population under evaluation was elderly, ill, and at high risk for death, it seems unlikely that pergolide played any role in these deaths, but the possibility that pergolide shortens survival of patients cannot be excluded with absolute certainty.
 
*In particular, a case-by-case review of the clinical course of the patients who died failed to disclose any unique set of signs, symptoms, or laboratory results that would suggest that treatment with pergolide caused their deaths. Sixty-eight percent (68%) of the patients who died were 65 years of age or older. No death (other than a suicide) occurred within the first month of treatment; most of the patients who died had been on pergolide for years. A relative frequency of the causes of death by organ system are: [[Pulmonary failure]]/[[Pneumonia]], 35%; Cardiovascular, 30%; [[Cancer]], 11%; Unknown, 8.4%; [[Infection]], 3.5%; [[Extrapyramidal syndrome]], 3.5%; [[Stroke]], 2.1%; [[Dysphagia]], 2.1%; Injury, 1.4%; [[Suicide]], 1.4%; [[Dehydration]], 0.7%; [[Glomerulonephritis]], 0.7%.
*In particular, a case-by-case review of the clinical course of the patients who died failed to disclose any unique set of signs, symptoms, or laboratory results that would suggest that treatment with pergolide caused their deaths. Sixty-eight percent (68%) of the patients who died were 65 years of age or older. No death (other than a suicide) occurred within the first month of treatment; most of the patients who died had been on pergolide for years. A relative frequency of the causes of death by organ system are: [[Pulmonary failure]]/[[Pneumonia]], 35%; Cardiovascular, 30%; [[Cancer]], 11%; Unknown, 8.4%; [[Infection]], 3.5%; [[Extrapyramidal syndrome]], 3.5%; [[Stroke]], 2.1%; [[Dysphagia]], 2.1%; Injury, 1.4%; [[Suicide]], 1.4%; [[Dehydration]], 0.7%; [[Glomerulonephritis]], 0.7%.
|clinicalTrials=====Commonly Observed====  
|clinicalTrials=====Commonly Observed====  
In premarketing clinical trials, the most commonly observed adverse events associated with use of pergolide which were not seen at an equivalent incidence among placebo-treated patients were: nervous system complaints, including [[dyskinesia]], [[hallucinations]], [[somnolence]], [[insomnia]]; digestive complaints, including [[nausea]], [[constipation]], [[diarrhea]], [[dyspepsia]]; and respiratory system complaints, including [[rhinitis]].
*In premarketing clinical trials, the most commonly observed adverse events associated with use of pergolide which were not seen at an equivalent incidence among placebo-treated patients were: nervous system complaints, including [[dyskinesia]], [[hallucinations]], [[somnolence]], [[insomnia]]; digestive complaints, including [[nausea]], [[constipation]], [[diarrhea]], [[dyspepsia]]; and respiratory system complaints, including [[rhinitis]].
*Associated With Discontinuation of Treatment: Twenty-seven percent (27%) of approximately 1200 patients receiving pergolide for treatment of [[Parkinson's disease]] in premarketing clinical trials in the US and Canada discontinued treatment due to adverse events. The events most commonly causing discontinuation were related to the nervous system (15.5%), primarily [[hallucinations]] (7.8%) and [[confusion]] (1.8%).
*Associated With Discontinuation of Treatment: Twenty-seven percent (27%) of approximately 1200 patients receiving pergolide for treatment of [[Parkinson's disease]] in premarketing clinical trials in the US and Canada discontinued treatment due to adverse events. The events most commonly causing discontinuation were related to the nervous system (15.5%), primarily [[hallucinations]] (7.8%) and [[confusion]] (1.8%).


Line 57: Line 49:
[[file:Pergolide AR.png|none|400px]]
[[file:Pergolide AR.png|none|400px]]


vents Observed During the Premarketing Evaluation of Permax— This section reports event frequencies evaluated as of October 1988 for adverse events occurring in a group of approximately 1800 patients who took multiple doses of pergolide. The conditions and duration of exposure to pergolide varied greatly, involving well-controlled studies as well as experience in open and uncontrolled clinical settings. In the absence of appropriate controls in some of the studies, a causal relationship between these events and treatment with pergolide cannot be determined.
*'''Events Observed During the Premarketing Evaluation of Pergolide'''— This section reports event frequencies evaluated as of October 1988 for adverse events occurring in a group of approximately 1800 patients who took multiple doses of pergolide. The conditions and duration of exposure to pergolide varied greatly, involving well-controlled studies as well as experience in open and uncontrolled clinical settings. In the absence of appropriate controls in some of the studies, a causal relationship between these events and treatment with pergolide cannot be determined.
 
*The following enumeration by organ system describes events in terms of their relative frequency of reporting in the data base. Events of major clinical importance are also described in the Warnings and Precautions sections.
The following enumeration by organ system describes events in terms of their relative frequency of reporting in the data base. Events of major clinical importance are also described in the Warnings and Precautions sections.
*The following definitions of frequency are used: frequent adverse events are defined as those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.
 
The following definitions of frequency are used: frequent adverse events are defined as those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.


====Body as a Whole====
====Body as a Whole====
Line 122: Line 112:
*Rare: [[amenorrhea]], [[bladder carcinoma]], [[breast engorgement]], [[epididymitis]], [[hypogonadism]], [[leukorrhea]], [[nephrosis]], [[pyelonephritis]], [[urethral pain]], [[uricaciduria]], [[withdrawal bleeding]].
*Rare: [[amenorrhea]], [[bladder carcinoma]], [[breast engorgement]], [[epididymitis]], [[hypogonadism]], [[leukorrhea]], [[nephrosis]], [[pyelonephritis]], [[urethral pain]], [[uricaciduria]], [[withdrawal bleeding]].
|postmarketing=====Postintroduction Reports====  
|postmarketing=====Postintroduction Reports====  
Voluntary reports of adverse events temporally associated with pergolide that have been received since market introduction and which may have no causal relationship with the drug, include the following: [[neuroleptic malignant syndrome]] and [[Raynaud’s phenomenon]].
*Voluntary reports of adverse events temporally associated with pergolide that have been received since market introduction and which may have no causal relationship with the drug, include the following: [[neuroleptic malignant syndrome]] and [[Raynaud’s phenomenon]].
|drugInteractions=[[Dopamine antagonists]], such as the [[neuroleptics]] ([[phenothiazines]], [[butyrophenones]], [[thioxanthines]]) or [[metoclopramide]], ordinarily should not be administered concurrently with Permax (a [[dopamine agonist]]); these agents may diminish the effectiveness of Permax.
|drugInteractions=*[[Dopamine antagonists]], such as the [[neuroleptics]] ([[phenothiazines]], [[butyrophenones]], [[thioxanthines]]) or [[metoclopramide]], ordinarily should not be administered concurrently with Pergolide (a [[dopamine agonist]]); these agents may diminish the effectiveness of Pergolide.
 
*Because pergolide is approximately 90% bound to plasma proteins, caution should be exercised if pergolide is coadministered with other drugs known to affect protein binding.
Because pergolide is approximately 90% bound to plasma proteins, caution should be exercised if pergolide is coadministered with other drugs known to affect protein binding.
|FDAPregCat=B
|FDAPregCat=B
|useInPregnancyFDA=Reproduction studies were conducted in mice at doses of 5, 16, and 45 mg/kg/day and in rabbits at doses of 2, 6, and 16 mg/kg/day. The highest doses tested in mice and rabbits were 375 and 133 times the 6 mg/day maximum human dose administered in controlled clinical trials. In these studies, there was no evidence of harm to the fetus due to pergolide.
|useInPregnancyFDA=*Reproduction studies were conducted in mice at doses of 5, 16, and 45 mg/kg/day and in rabbits at doses of 2, 6, and 16 mg/kg/day. The highest doses tested in mice and rabbits were 375 and 133 times the 6 mg/day maximum human dose administered in controlled clinical trials. In these studies, there was no evidence of harm to the fetus due to pergolide.
 
*There are, however, no adequate and well-controlled studies in pregnant women. Among women who received pergolide for endocrine disorders in premarketing studies, there were 33 pregnancies that resulted in healthy babies and 6 pregnancies that resulted in congenital abnormalities (3 major, 3 minor); a causal relationship has not been established. Because human data are limited and because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
There are, however, no adequate and well-controlled studies in pregnant women. Among women who received pergolide for endocrine disorders in premarketing studies, there were 33 pregnancies that resulted in healthy babies and 6 pregnancies that resulted in congenital abnormalities (3 major, 3 minor); a causal relationship has not been established. Because human data are limited and because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
|useInNursing=*It is not known whether this drug is excreted in human milk. The pharmacologic action of pergolide suggests that it may interfere with lactation. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions to pergolide in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
|useInNursing=It is not known whether this drug is excreted in human milk. The pharmacologic action of pergolide suggests that it may interfere with lactation. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions to pergolide in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
|useInPed=*Safety and effectiveness in pediatric patients have not been established.
|useInPed=Safety and effectiveness in pediatric patients have not been established.
|useInGeri=*Of the total number of subjects in clinical studies of pergolide, 78 were 65 and over. There were no apparent differences in efficacy between these subjects and younger subjects. There was an increased incidence of [[confusion]], [[somnolence]], and [[peripheral edema]] in patients 65 and over. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with [[impaired renal function]]. Because elderly patients are more likely to have decreased [[renal function]], care should be taken in dose selection, and it may be useful to monitor [[renal function]].
|useInGeri=Of the total number of subjects in clinical studies of pergolide, 78 were 65 and over. There were no apparent differences in efficacy between these subjects and younger subjects. There was an increased incidence of [[confusion]], [[somnolence]], and [[peripheral edema]] in patients 65 and over. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with [[impaired renal function]]. Because elderly patients are more likely to have decreased [[renal function]], care should be taken in dose selection, and it may be useful to monitor [[renal function]].
|overdose=*There is no clinical experience with massive overdosage. The largest overdose involved a young hospitalized adult patient who was not being treated with pergolide but who intentionally took 60 mg of the drug. He experienced [[vomiting]], [[hypotension]], and [[agitation]]. Another patient receiving a daily dosage of 7 mg of pergolide unintentionally took 19 mg/day for 3 days, after which his vital signs were normal but he experienced severe hallucinations. Within 36 hours of resumption of the prescribed dosage level, the [[hallucinations]] stopped. One patient unintentionally took 14 mg/day for 23 days instead of her prescribed 1.4 mg/day dosage. She experienced severe involuntary movements and tingling in her arms and legs. Another patient who inadvertently received 7 mg instead of the prescribed 0.7 mg experienced [[palpitations]], [[hypotension]], and [[ventricular extrasystoles]]. The highest total daily dose (prescribed for several patients with refractory [[Parkinson's disease]]) has exceeded 30 mg.
|overdose=There is no clinical experience with massive overdosage. The largest overdose involved a young hospitalized adult patient who was not being treated with pergolide but who intentionally took 60 mg of the drug. He experienced [[vomiting]], [[hypotension]], and [[agitation]]. Another patient receiving a daily dosage of 7 mg of pergolide unintentionally took 19 mg/day for 3 days, after which his vital signs were normal but he experienced severe hallucinations. Within 36 hours of resumption of the prescribed dosage level, the [[hallucinations]] stopped. One patient unintentionally took 14 mg/day for 23 days instead of her prescribed 1.4 mg/day dosage. She experienced severe involuntary movements and tingling in her arms and legs. Another patient who inadvertently received 7 mg instead of the prescribed 0.7 mg experienced [[palpitations]], [[hypotension]], and [[ventricular extrasystoles]]. The highest total daily dose (prescribed for several patients with refractory [[Parkinson's disease]]) has exceeded 30 mg.
 
*Symptoms— Animal studies indicate that the manifestations of overdosage in man might include [[nausea]], [[vomiting]], [[convulsions]], [[hypotension]], and [[CNS stimulation]]. The oral median lethal doses in mice and rats were 54 and 15 mg/kg respectively.
*Symptoms— Animal studies indicate that the manifestations of overdosage in man might include [[nausea]], [[vomiting]], [[convulsions]], [[hypotension]], and [[CNS stimulation]]. The oral median lethal doses in mice and rats were 54 and 15 mg/kg respectively.
*Treatment— To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.
*Treatment— To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.
 
*Management of overdosage may require supportive measures to maintain [[arterial blood pressure]]. [[Cardiac function]] should be monitored; an [[antiarrhythmic agent]] may be necessary. If signs of CNS stimulation are present, a [[phenothiazine]] or other [[butyrophenone neuroleptic agent]] may be indicated; the efficacy of such drugs in reversing the effects of overdose has not been assessed.
Management of overdosage may require supportive measures to maintain [[arterial blood pressure]]. [[Cardiac function]] should be monitored; an [[antiarrhythmic agent]] may be necessary. If signs of CNS stimulation are present, a [[phenothiazine]] or other [[butyrophenone neuroleptic agent]] may be indicated; the efficacy of such drugs in reversing the effects of overdose has not been assessed.
*Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s [[vital signs]], [[blood gases]], [[serum electrolytes]], etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving [[activated charcoal]], which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient’s airway when employing gastric emptying or charcoal.
 
*There is no experience with dialysis or hemoperfusion, and these procedures are unlikely to be of benefit.
Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s [[vital signs]], [[blood gases]], [[serum electrolytes]], etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving [[activated charcoal]], which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient’s airway when employing gastric emptying or charcoal.
 
There is no experience with dialysis or hemoperfusion, and these procedures are unlikely to be of benefit.
|drugBox={{Drugbox2
|drugBox={{Drugbox2
| Verifiedfields = changed
| Verifiedfields = changed
Line 196: Line 179:
| synonyms = <small>(6a''R'',9''R'',10a''R'')-9-(methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-''fg'']quinoline</small>
| synonyms = <small>(6a''R'',9''R'',10a''R'')-9-(methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-''fg'']quinoline</small>
}}
}}
|structure=Pergolide mesylate is chemically designated as 8β-(Methylthio)methyl-6-propylergoline monomethanesulfonate; the structural formula is as follows:
|structure=*Pergolide mesylate is chemically designated as 8β-(Methylthio)methyl-6-propylergoline monomethanesulfonate; the structural formula is as follows:


[[file:Pergolide Structure.png|none|300px]]
[[file:Pergolide Structure.png|none|300px]]


The empirical formula is C19H26N2S∙CH4O3S, representing a molecular weight of 410.60.
The empirical formula is C19H26N2S∙CH4O3S, representing a molecular weight of 410.60.
|PD=Pergolide is a potent [[dopamine agonist]]. Pergolide is 10 to 1000 times more potent than [[bromocriptine]] on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide inhibits the secretion of [[prolactin]] in humans; it causes a transient rise in serum concentrations of [[growth hormone]] and a decrease in serum concentrations of [[luteinizing hormone]]. In [[Parkinson's disease]], pergolide is believed to exert its therapeutic effect by directly stimulating postsynaptic [[dopamine receptors]] in the [[nigrostriatal system]].
|PD=*Pergolide is a potent [[dopamine agonist]]. Pergolide is 10 to 1000 times more potent than [[bromocriptine]] on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide inhibits the secretion of [[prolactin]] in humans; it causes a transient rise in serum concentrations of [[growth hormone]] and a decrease in serum concentrations of [[luteinizing hormone]]. In [[Parkinson's disease]], pergolide is believed to exert its therapeutic effect by directly stimulating postsynaptic [[dopamine receptors]] in the [[nigrostriatal system]].
|PK======Absorption=====
|PK======Absorption=====
Information on oral systemic bioavailability of pergolide is unavailable because of the lack of a sufficiently sensitive assay to detect the drug after the administration of a single dose. However, following oral administration of 14C radiolabeled pergolide, approximately 55% of the administered radioactivity can be recovered from the urine and 5% from expired CO2, suggesting that a significant fraction is absorbed. Nothing can be concluded about the extent of presystemic clearance, if any.
*Information on oral systemic bioavailability of pergolide is unavailable because of the lack of a sufficiently sensitive assay to detect the drug after the administration of a single dose. However, following oral administration of 14C radiolabeled pergolide, approximately 55% of the administered radioactivity can be recovered from the urine and 5% from expired CO2, suggesting that a significant fraction is absorbed. Nothing can be concluded about the extent of presystemic clearance, if any.


=====Distribution=====
=====Distribution=====
Pergolide is approximately 90% bound to plasma proteins. This extent of protein binding may be important to consider when pergolide is coadministered with other drugs known to affect protein binding.
*Pergolide is approximately 90% bound to plasma proteins. This extent of protein binding may be important to consider when pergolide is coadministered with other drugs known to affect protein binding.
Data on postabsorption distribution of pergolide are unavailable.
*Data on postabsorption distribution of pergolide are unavailable.


=====Metabolism=====
=====Metabolism=====
At least 10 metabolites have been detected, including N-despropylpergolide, pergolide sulfoxide, and pergolide sulfone. Pergolide sulfoxide and pergolide sulfone are dopamine agonists in animals. The other detected metabolites have not been identified and it is not known whether any other metabolites are active pharmacologically.
*At least 10 metabolites have been detected, including N-despropylpergolide, pergolide sulfoxide, and pergolide sulfone.  
*Pergolide sulfoxide and pergolide sulfone are dopamine agonists in animals. The other detected metabolites have not been identified and it is not known whether any other metabolites are active pharmacologically.


=====Excretion=====
=====Excretion=====
The major route of excretion is the kidney.
*The major route of excretion is the kidney.
|nonClinToxic=A 2-year carcinogenicity study was conducted in mice using dietary levels of pergolide equivalent to oral doses of 0.6, 3.7, and 36.4 mg/kg/day in males and 0.6, 4.4, and 40.8 mg/kg/day in females. A 2-year study in rats was conducted using dietary levels equivalent to oral doses of 0.04, 0.18, and 0.88 mg/kg/day in males and 0.05, 0.28, and 1.42 mg/kg/day in females. The highest doses tested in the mice and rats were approximately 340 and 12 times the maximum human oral dose administered in controlled clinical trials (6 mg/day equivalent to 0.12 mg/kg/day).
|nonClinToxic=*A 2-year carcinogenicity study was conducted in mice using dietary levels of pergolide equivalent to oral doses of 0.6, 3.7, and 36.4 mg/kg/day in males and 0.6, 4.4, and 40.8 mg/kg/day in females. A 2-year study in rats was conducted using dietary levels equivalent to oral doses of 0.04, 0.18, and 0.88 mg/kg/day in males and 0.05, 0.28, and 1.42 mg/kg/day in females. The highest doses tested in the mice and rats were approximately 340 and 12 times the maximum human oral dose administered in controlled clinical trials (6 mg/day equivalent to 0.12 mg/kg/day).
 
*A low incidence of uterine neoplasms occurred in both rats and mice. [[Endometrial adenomas]] and [[carcinomas]] were observed in rats. [[Endometrial sarcomas]] were observed in mice. The occurrence of these neoplasms is probably attributable to the high [[estrogen/progesterone ratio]] that would occur in rodents as a result of the [[prolactin]]-inhibiting action of pergolide. The endocrine mechanisms believed to be involved in the rodents are not present in humans. However, even though there is no known correlation between uterine malignancies occurring in pergolide-treated rodents and human risk, there are no human data to substantiate this conclusion.
A low incidence of uterine neoplasms occurred in both rats and mice. Endometrial adenomas and carcinomas were observed in rats. [[Endometrial sarcomas]] were observed in mice. The occurrence of these neoplasms is probably attributable to the high [[estrogen/progesterone ratio]] that would occur in rodents as a result of the [[prolactin]]-inhibiting action of pergolide. The endocrine mechanisms believed to be involved in the rodents are not present in humans. However, even though there is no known correlation between uterine malignancies occurring in pergolide-treated rodents and human risk, there are no human data to substantiate this conclusion.
*Pergolide was evaluated for mutagenic potential in a battery of tests that included an Ames bacterial mutation assay, a [[DNA]] repair assay in cultured rat [[hepatocytes]], an in vitro mammalian cell gene mutation assay in cultured L5178Y cells, and a determination of [[chromosome]] alteration in [[bone marrow]] cells of Chinese hamsters. A weak mutagenic response was noted in the mammalian cell gene mutation assay only after metabolic activation with rat liver microsomes. No mutagenic effects were obtained in the 2 other in vitro assays and in the in vivo assay. The relevance of these findings in humans is unknown.
 
*A fertility study in male and female mice showed that fertility was maintained at 0.6 and 1.7 mg/kg/day but decreased at 5.6 mg/kg/day. Prolactin has been reported to be involved in stimulating and maintaining progesterone levels required for implantation in mice and, therefore, the impaired fertility at the high dose may have occurred because of depressed [[prolactin]] levels.
Pergolide was evaluated for mutagenic potential in a battery of tests that included an Ames bacterial mutation assay, a [[DNA]] repair assay in cultured rat [[hepatocytes]], an in vitro mammalian cell gene mutation assay in cultured L5178Y cells, and a determination of [[chromosome]] alteration in [[bone marrow]] cells of Chinese hamsters. A weak mutagenic response was noted in the mammalian cell gene mutation assay only after metabolic activation with rat liver microsomes. No mutagenic effects were obtained in the 2 other in vitro assays and in the in vivo assay. The relevance of these findings in humans is unknown.
 
A fertility study in male and female mice showed that fertility was maintained at 0.6 and 1.7 mg/kg/day but decreased at 5.6 mg/kg/day. Prolactin has been reported to be involved in stimulating and maintaining progesterone levels required for implantation in mice and, therefore, the impaired fertility at the high dose may have occurred because of depressed [[prolactin]] levels.
|howSupplied=Tablets (modified rectangle shape, scored):
|howSupplied=Tablets (modified rectangle shape, scored):
*0.05 mg, ivory, debossed with A 024, in bottles of 30 (UC5336) — NDC 0187-0839-01
*0.05 mg, ivory, debossed with A 024, in bottles of 30 (UC5336) — NDC 0187-0839-01
*0.25 mg, green, debossed with A 025, in bottles of 100 (UC5337) — NDC 0187-0840-02
*0.25 mg, green, debossed with A 025, in bottles of 100 (UC5337) — NDC 0187-0840-02
*1 mg, pink, debossed with A 026, in bottles of 100 (UC5338) — NDC 0187-0841-02
*1 mg, pink, debossed with A 026, in bottles of 100 (UC5338) — NDC 0187-0841-02
|storage=Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F)  
|storage=*Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F)
|packLabel=[[file:Pergolide Appearance.png|none|400px]
|packLabel=[[file:Pergolide Appearance.png|none|400px]]
|alcohol=Alcohol-Pergolide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=*Alcohol-Pergolide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|brandNames=*[[Permax]]
|brandNames=*[[Permax]]
}}
}}

Latest revision as of 16:39, 27 February 2015

Pergolide
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Cardiac Valvulopathy and Fibrotic Complications
See full prescribing information for complete Boxed Warning.
Cardiac Valvulopathy:
  • The use of pergolide has been shown to increase the risk of cardiac valvular disease involving one or more valves. Some patients have required valve replacement, and deaths have been reported. Cases have been reported after exposures to pergolide ranging from several months to several years. The histopathology of explanted valves is similar to that of other drug-induced valvulopathies. Precise risk estimates of pergolide-induced cardiac valvular disease are not available.
  • Specific risk factors predisposing patients to developing cardiac valvular disease with pergolide have not been identified. Cardiac valvulopathy has been reported with all doses of pergolide; however, available data suggest that the risk may be greater with higher doses. Doses of pergolide above 5 mg/day are not recommended.
  • Pergolide is not recommended for use in patients with a history of cardiac valvulopathy.
  • Before initiating treatment with pergolide, all patients should undergo a cardiovascular evaluation, including an echocardiogram, to determine whether valvular disease is present and to provide a baseline for subsequent monitoring.
  • Although the risk of disease progression in patients with asymptomatic valvular disease is unknown, pergolide ordinarily should not be initiated if valvulopathy is detected at screening.
  • All patients taking pergolide should undergo periodic echocardiograms to screen for the development of valvulopathy. Patients should also be monitored for signs and symptoms of valvulopathy, including dyspnea, edema, congestive heart failure and new cardiac murmurs. If a patient develops these signs or symptoms, consideration should be given to suspending treatment with pergolide until a full diagnostic evaluation, including echocardiogram, has been performed. Pergolide should ordinarily be discontinued if a patient is diagnosed with cardiac valvular disease. In some cases, signs and/or symptoms of cardiac valvulopathy improved after discontinuation of pergolide.


Fibrotic Complications:

  • Case reports have demonstrated that pergolide increases the risk of fibrotic complications including pulmonary, pleural, and/or retroperitoneal fibrosis, pericarditis, pleuritis, and pericardial and/or pleural effusions. Cases have been reported after exposures to pergolide ranging from about one to several years. Precise risk estimates of pergolide-induced fibrotic complications are not available.
  • Specific risk factors predisposing patients to developing fibrotic complications with pergolide have not been identified. Fibrotic complications have been reported with all therapeutic doses of pergolide.
  • Pergolide is not recommended for use in patients with a history of fibrotic conditions.
  • Patients should also be monitored for signs and symptoms of fibrotic complications, including dyspnea, persistent edema, cough, congestive heart failure, new cardiac rub, and/or signs of urinary tract obstruction. If a patient develops these signs or symptoms, consideration should be given to suspending treatment with pergolide until a full diagnostic evaluation has been performed. Pergolide should ordinarily be discontinued if a patient is diagnosed with a specific fibrotic complication. In some cases, signs and/or symptoms of fibrotic complications improved after discontinuation of pergolide.

Overview

Pergolide is an antiparkinsonian, autonomic, central nervous system agent, dopamine agonist that is FDA approved for the treatment of Parkinson's disease as an adjunctive treatment with carbidopa/levodopa. There is a Black Box Warning for this drug as shown here. Common adverse reactions include dyskinesia, hallucinations, somnolence, insomnia, nausea, constipation, diarrhea, dyspepsia and rhinitis.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Administration of Pergolide should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
  • Pergolide is usually administered in divided doses 3 times per day. During dosage titration, the dosage of concurrent l-dopa/carbidopa may be cautiously decreased.
  • In clinical studies, the mean therapeutic daily dosage of Pergolide was 3 mg/day. The average concurrent daily dosage of l-dopa/carbidopa (expressed as l-dopa) was approximately 650 mg/day. The efficacy of Pergolide at doses above 5 mg/day has not been systematically evaluated. Doses of pergolide above 5 mg/day are not recommended.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pergolide in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Pergolide in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Pergolide FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pergolide in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Pergolide in pediatric patients.

Contraindications

  • Pergolide is contraindicated in patients who are hypersensitive to this drug or other ergot derivatives.

Warnings

Cardiac Valvulopathy and Fibrotic Complications
See full prescribing information for complete Boxed Warning.
Cardiac Valvulopathy:
  • The use of pergolide has been shown to increase the risk of cardiac valvular disease involving one or more valves. Some patients have required valve replacement, and deaths have been reported. Cases have been reported after exposures to pergolide ranging from several months to several years. The histopathology of explanted valves is similar to that of other drug-induced valvulopathies. Precise risk estimates of pergolide-induced cardiac valvular disease are not available.
  • Specific risk factors predisposing patients to developing cardiac valvular disease with pergolide have not been identified. Cardiac valvulopathy has been reported with all doses of pergolide; however, available data suggest that the risk may be greater with higher doses. Doses of pergolide above 5 mg/day are not recommended.
  • Pergolide is not recommended for use in patients with a history of cardiac valvulopathy.
  • Before initiating treatment with pergolide, all patients should undergo a cardiovascular evaluation, including an echocardiogram, to determine whether valvular disease is present and to provide a baseline for subsequent monitoring.
  • Although the risk of disease progression in patients with asymptomatic valvular disease is unknown, pergolide ordinarily should not be initiated if valvulopathy is detected at screening.
  • All patients taking pergolide should undergo periodic echocardiograms to screen for the development of valvulopathy. Patients should also be monitored for signs and symptoms of valvulopathy, including dyspnea, edema, congestive heart failure and new cardiac murmurs. If a patient develops these signs or symptoms, consideration should be given to suspending treatment with pergolide until a full diagnostic evaluation, including echocardiogram, has been performed. Pergolide should ordinarily be discontinued if a patient is diagnosed with cardiac valvular disease. In some cases, signs and/or symptoms of cardiac valvulopathy improved after discontinuation of pergolide.


Fibrotic Complications:

  • Case reports have demonstrated that pergolide increases the risk of fibrotic complications including pulmonary, pleural, and/or retroperitoneal fibrosis, pericarditis, pleuritis, and pericardial and/or pleural effusions. Cases have been reported after exposures to pergolide ranging from about one to several years. Precise risk estimates of pergolide-induced fibrotic complications are not available.
  • Specific risk factors predisposing patients to developing fibrotic complications with pergolide have not been identified. Fibrotic complications have been reported with all therapeutic doses of pergolide.
  • Pergolide is not recommended for use in patients with a history of fibrotic conditions.
  • Patients should also be monitored for signs and symptoms of fibrotic complications, including dyspnea, persistent edema, cough, congestive heart failure, new cardiac rub, and/or signs of urinary tract obstruction. If a patient develops these signs or symptoms, consideration should be given to suspending treatment with pergolide until a full diagnostic evaluation has been performed. Pergolide should ordinarily be discontinued if a patient is diagnosed with a specific fibrotic complication. In some cases, signs and/or symptoms of fibrotic complications improved after discontinuation of pergolide.

Cardiac Valvulopathy and Fibrotic Complications

  • Falling Asleep During Activities of Daily Living—Patients treated with Pergolide have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles which sometimes resulted in accidents. Although many of these patients reported somnolence while on Pergolide some perceived that they had no warning signs such as excessive drowsiness, and believed that they were alert immediately prior to the event. Some of these events had been reported as late as 1 year after the initiation of treatment.
  • Somnolence is a common occurrence in patients receiving Pergolide — Many clinical experts believe that falling asleep while engaged in activities of daily living always occurs in a setting of preexisting somnolence, although patients may not give such a history. For this reason, prescribers should continually reassess patients for drowsiness or sleepiness, especially since some of the events occur well after the start of treatment. Prescribers should also be aware that patients may not acknowledge drowsiness or sleepiness until directly questioned about drowsiness or sleepiness during specific activities.
  • Before initiating treatment with Pergolide, patients should be advised of the potential to develop drowsiness and specifically asked about factors that may increase the risk with Pergolide such as concomitant sedating medications or the presence of sleep disorders. If a patient develops significant daytime sleepiness or episodes of falling asleep during activities that require participation (e.g., conversations, eating, etc.), Pergolide should ordinarily be discontinued. *If a decision is made to continue Pergolide, patients should be advised to not drive and to avoid other potentially dangerous activities.
    • While dose reduction may reduce the degree of somnolence, there is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living.
  • Symptomatic Hypotension — In clinical trials, approximately 10% of patients taking pergolide with l-dopa versus 7% taking placebo with l-dopa experienced symptomatic orthostatic hypotension and/or sustained hypotension, especially during initial treatment. With gradual dosage titration, tolerance to the hypotension usually develops. It is therefore important to warn patients of the risk, to begin therapy with low doses, and to increase the dosage in carefully adjusted increments over a period of 3 to 4 weeks.
  • Hallucinosis— In controlled trials, pergolide with l-dopa caused hallucinosis in about 14% of patients as opposed to 3% taking placebo with l-dopa. This was of sufficient severity to cause discontinuation of treatment in about 3% of those enrolled; tolerance to this untoward effect was not observed.
  • Fatalities— In the placebo-controlled trial, 2 of 187 patients treated with placebo died as compared with 1 of 189 patients treated with pergolide. Of the 2299 patients treated with pergolide in premarketing studies evaluated as of October 1988, 143 died while on the drug or shortly after discontinuing it. Because the patient population under evaluation was elderly, ill, and at high risk for death, it seems unlikely that pergolide played any role in these deaths, but the possibility that pergolide shortens survival of patients cannot be excluded with absolute certainty.
  • In particular, a case-by-case review of the clinical course of the patients who died failed to disclose any unique set of signs, symptoms, or laboratory results that would suggest that treatment with pergolide caused their deaths. Sixty-eight percent (68%) of the patients who died were 65 years of age or older. No death (other than a suicide) occurred within the first month of treatment; most of the patients who died had been on pergolide for years. A relative frequency of the causes of death by organ system are: Pulmonary failure/Pneumonia, 35%; Cardiovascular, 30%; Cancer, 11%; Unknown, 8.4%; Infection, 3.5%; Extrapyramidal syndrome, 3.5%; Stroke, 2.1%; Dysphagia, 2.1%; Injury, 1.4%; Suicide, 1.4%; Dehydration, 0.7%; Glomerulonephritis, 0.7%.

Adverse Reactions

Clinical Trials Experience

Commonly Observed

  • In premarketing clinical trials, the most commonly observed adverse events associated with use of pergolide which were not seen at an equivalent incidence among placebo-treated patients were: nervous system complaints, including dyskinesia, hallucinations, somnolence, insomnia; digestive complaints, including nausea, constipation, diarrhea, dyspepsia; and respiratory system complaints, including rhinitis.
  • Associated With Discontinuation of Treatment: Twenty-seven percent (27%) of approximately 1200 patients receiving pergolide for treatment of Parkinson's disease in premarketing clinical trials in the US and Canada discontinued treatment due to adverse events. The events most commonly causing discontinuation were related to the nervous system (15.5%), primarily hallucinations (7.8%) and confusion (1.8%).

Fatalities

  • Incidence in Controlled Clinical Trials: The table that follows enumerates adverse events that occurred at a frequency of 1% or more among patients taking pergolide who participated in the premarketing controlled clinical trials comparing pergolide with placebo. In a double-blind, controlled study of 6 months’ duration, patients with Parkinson’s disease were continued on l-dopa/carbidopa and were randomly assigned to receive either pergolide or placebo as additional therapy. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side-effect incidence rate in the population studied.
  • Events Observed During the Premarketing Evaluation of Pergolide— This section reports event frequencies evaluated as of October 1988 for adverse events occurring in a group of approximately 1800 patients who took multiple doses of pergolide. The conditions and duration of exposure to pergolide varied greatly, involving well-controlled studies as well as experience in open and uncontrolled clinical settings. In the absence of appropriate controls in some of the studies, a causal relationship between these events and treatment with pergolide cannot be determined.
  • The following enumeration by organ system describes events in terms of their relative frequency of reporting in the data base. Events of major clinical importance are also described in the Warnings and Precautions sections.
  • The following definitions of frequency are used: frequent adverse events are defined as those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.

Body as a Whole

Cardiovascular System

Digestive System

Endocrine System

Hemic and Lymphatic System

Metabolic and Nutritional System

Musculoskeletal System

Nervous System

Respiratory System

Skin and Appendages System

Special Senses System

Urogenital System

Postmarketing Experience

Postintroduction Reports

  • Voluntary reports of adverse events temporally associated with pergolide that have been received since market introduction and which may have no causal relationship with the drug, include the following: neuroleptic malignant syndrome and Raynaud’s phenomenon.

Drug Interactions

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): B

  • Reproduction studies were conducted in mice at doses of 5, 16, and 45 mg/kg/day and in rabbits at doses of 2, 6, and 16 mg/kg/day. The highest doses tested in mice and rabbits were 375 and 133 times the 6 mg/day maximum human dose administered in controlled clinical trials. In these studies, there was no evidence of harm to the fetus due to pergolide.
  • There are, however, no adequate and well-controlled studies in pregnant women. Among women who received pergolide for endocrine disorders in premarketing studies, there were 33 pregnancies that resulted in healthy babies and 6 pregnancies that resulted in congenital abnormalities (3 major, 3 minor); a causal relationship has not been established. Because human data are limited and because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.


Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pergolide in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Pergolide during labor and delivery.

Nursing Mothers

  • It is not known whether this drug is excreted in human milk. The pharmacologic action of pergolide suggests that it may interfere with lactation. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions to pergolide in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

  • Safety and effectiveness in pediatric patients have not been established.

Geriatic Use

  • Of the total number of subjects in clinical studies of pergolide, 78 were 65 and over. There were no apparent differences in efficacy between these subjects and younger subjects. There was an increased incidence of confusion, somnolence, and peripheral edema in patients 65 and over. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Gender

There is no FDA guidance on the use of Pergolide with respect to specific gender populations.

Race

There is no FDA guidance on the use of Pergolide with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Pergolide in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Pergolide in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Pergolide in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Pergolide in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Pergolide Administration in the drug label.

Monitoring

There is limited information regarding Pergolide Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Pergolide and IV administrations.

Overdosage

  • There is no clinical experience with massive overdosage. The largest overdose involved a young hospitalized adult patient who was not being treated with pergolide but who intentionally took 60 mg of the drug. He experienced vomiting, hypotension, and agitation. Another patient receiving a daily dosage of 7 mg of pergolide unintentionally took 19 mg/day for 3 days, after which his vital signs were normal but he experienced severe hallucinations. Within 36 hours of resumption of the prescribed dosage level, the hallucinations stopped. One patient unintentionally took 14 mg/day for 23 days instead of her prescribed 1.4 mg/day dosage. She experienced severe involuntary movements and tingling in her arms and legs. Another patient who inadvertently received 7 mg instead of the prescribed 0.7 mg experienced palpitations, hypotension, and ventricular extrasystoles. The highest total daily dose (prescribed for several patients with refractory Parkinson's disease) has exceeded 30 mg.
  • Symptoms— Animal studies indicate that the manifestations of overdosage in man might include nausea, vomiting, convulsions, hypotension, and CNS stimulation. The oral median lethal doses in mice and rats were 54 and 15 mg/kg respectively.
  • Treatment— To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.
  • Management of overdosage may require supportive measures to maintain arterial blood pressure. Cardiac function should be monitored; an antiarrhythmic agent may be necessary. If signs of CNS stimulation are present, a phenothiazine or other butyrophenone neuroleptic agent may be indicated; the efficacy of such drugs in reversing the effects of overdose has not been assessed.
  • Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient’s airway when employing gastric emptying or charcoal.
  • There is no experience with dialysis or hemoperfusion, and these procedures are unlikely to be of benefit.

Pharmacology

Template:Px
Pergolide
Systematic (IUPAC) name
(8β)-8-[(methylthio)methyl]-6-propylergoline
Identifiers
CAS number 66104-22-1
ATC code N04BC02
PubChem 47811
DrugBank DB01186
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 314.489 g/mol
SMILES eMolecules & PubChem
Synonyms (6aR,9R,10aR)-9-(methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline
Pharmacokinetic data
Bioavailability ?
Protein binding 90%
Metabolism Extensively hepatic
Half life 27 hours
Excretion ?
Therapeutic considerations
Pregnancy cat.

B

Legal status

Withdrawn (U.S.)

Routes Oral

Mechanism of Action

There is limited information regarding Pergolide Mechanism of Action in the drug label.

Structure

  • Pergolide mesylate is chemically designated as 8β-(Methylthio)methyl-6-propylergoline monomethanesulfonate; the structural formula is as follows:

The empirical formula is C19H26N2S∙CH4O3S, representing a molecular weight of 410.60.

Pharmacodynamics

Pharmacokinetics

Absorption
  • Information on oral systemic bioavailability of pergolide is unavailable because of the lack of a sufficiently sensitive assay to detect the drug after the administration of a single dose. However, following oral administration of 14C radiolabeled pergolide, approximately 55% of the administered radioactivity can be recovered from the urine and 5% from expired CO2, suggesting that a significant fraction is absorbed. Nothing can be concluded about the extent of presystemic clearance, if any.
Distribution
  • Pergolide is approximately 90% bound to plasma proteins. This extent of protein binding may be important to consider when pergolide is coadministered with other drugs known to affect protein binding.
  • Data on postabsorption distribution of pergolide are unavailable.
Metabolism
  • At least 10 metabolites have been detected, including N-despropylpergolide, pergolide sulfoxide, and pergolide sulfone.
  • Pergolide sulfoxide and pergolide sulfone are dopamine agonists in animals. The other detected metabolites have not been identified and it is not known whether any other metabolites are active pharmacologically.
Excretion
  • The major route of excretion is the kidney.

Nonclinical Toxicology

  • A 2-year carcinogenicity study was conducted in mice using dietary levels of pergolide equivalent to oral doses of 0.6, 3.7, and 36.4 mg/kg/day in males and 0.6, 4.4, and 40.8 mg/kg/day in females. A 2-year study in rats was conducted using dietary levels equivalent to oral doses of 0.04, 0.18, and 0.88 mg/kg/day in males and 0.05, 0.28, and 1.42 mg/kg/day in females. The highest doses tested in the mice and rats were approximately 340 and 12 times the maximum human oral dose administered in controlled clinical trials (6 mg/day equivalent to 0.12 mg/kg/day).
  • A low incidence of uterine neoplasms occurred in both rats and mice. Endometrial adenomas and carcinomas were observed in rats. Endometrial sarcomas were observed in mice. The occurrence of these neoplasms is probably attributable to the high estrogen/progesterone ratio that would occur in rodents as a result of the prolactin-inhibiting action of pergolide. The endocrine mechanisms believed to be involved in the rodents are not present in humans. However, even though there is no known correlation between uterine malignancies occurring in pergolide-treated rodents and human risk, there are no human data to substantiate this conclusion.
  • Pergolide was evaluated for mutagenic potential in a battery of tests that included an Ames bacterial mutation assay, a DNA repair assay in cultured rat hepatocytes, an in vitro mammalian cell gene mutation assay in cultured L5178Y cells, and a determination of chromosome alteration in bone marrow cells of Chinese hamsters. A weak mutagenic response was noted in the mammalian cell gene mutation assay only after metabolic activation with rat liver microsomes. No mutagenic effects were obtained in the 2 other in vitro assays and in the in vivo assay. The relevance of these findings in humans is unknown.
  • A fertility study in male and female mice showed that fertility was maintained at 0.6 and 1.7 mg/kg/day but decreased at 5.6 mg/kg/day. Prolactin has been reported to be involved in stimulating and maintaining progesterone levels required for implantation in mice and, therefore, the impaired fertility at the high dose may have occurred because of depressed prolactin levels.

Clinical Studies

There is limited information regarding Pergolide Clinical Studies in the drug label.

How Supplied

Tablets (modified rectangle shape, scored):

  • 0.05 mg, ivory, debossed with A 024, in bottles of 30 (UC5336) — NDC 0187-0839-01
  • 0.25 mg, green, debossed with A 025, in bottles of 100 (UC5337) — NDC 0187-0840-02
  • 1 mg, pink, debossed with A 026, in bottles of 100 (UC5338) — NDC 0187-0841-02

Storage

  • Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F)

Images

Drug Images

{{#ask: Page Name::Pergolide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Pergolide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Pergolide Patient Counseling Information in the drug label.

Precautions with Alcohol

  • Alcohol-Pergolide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

There is limited information regarding Pergolide Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Retrieved from "https://www.wikidoc.org/index.php?title=Pergolide&oldid=1073997"